vs
ARDELYX, INC.（ARDX）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
ARDELYX, INC.的季度营收约是RIGEL PHARMACEUTICALS INC的1.4倍（$94.5M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -39.8%，领先423.8%），ARDELYX, INC.同比增速更快（27.5% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 13.6%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ARDX vs RIGL — 直观对比
营收规模更大
ARDX
是对方的1.4倍
$69.8M
营收增速更快
ARDX
高出6.3%
21.2%
净利率更高
RIGL
高出423.8%
-39.8%
两年增速更快
RIGL
近两年复合增速
13.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $69.8M |
| 净利润 | $-37.6M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | -39.8% | 384.0% |
| 营收同比 | 27.5% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-0.15 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXRIGL
| Q1 26 | $94.5M | — | ||
| Q4 25 | $125.2M | $69.8M | ||
| Q3 25 | $110.3M | $69.5M | ||
| Q2 25 | $97.7M | $101.7M | ||
| Q1 25 | $74.1M | $53.3M | ||
| Q4 24 | $116.1M | $57.6M | ||
| Q3 24 | $98.2M | $55.3M | ||
| Q2 24 | $73.2M | $36.8M |
净利润ARDXRIGL
| Q1 26 | $-37.6M | — | ||
| Q4 25 | $-407.0K | $268.1M | ||
| Q3 25 | $-969.0K | $27.9M | ||
| Q2 25 | $-19.1M | $59.6M | ||
| Q1 25 | $-41.1M | $11.4M | ||
| Q4 24 | $4.6M | $14.3M | ||
| Q3 24 | $-809.0K | $12.4M | ||
| Q2 24 | $-16.5M | $-1.0M |
毛利率ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | 91.5% | ||
| Q3 25 | 96.4% | 93.2% | ||
| Q2 25 | 87.3% | 95.6% | ||
| Q1 25 | 83.4% | 91.7% | ||
| Q4 24 | 84.3% | 89.9% | ||
| Q3 24 | 84.0% | 85.5% | ||
| Q2 24 | 87.1% | 92.4% |
营业利润率ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 33.2% | ||
| Q3 25 | 4.2% | 40.9% | ||
| Q2 25 | -14.7% | 60.1% | ||
| Q1 25 | -49.0% | 23.9% | ||
| Q4 24 | 7.0% | 28.9% | ||
| Q3 24 | 2.3% | 25.4% | ||
| Q2 24 | -18.6% | 1.2% |
净利率ARDXRIGL
| Q1 26 | -39.8% | — | ||
| Q4 25 | -0.3% | 384.0% | ||
| Q3 25 | -0.9% | 40.2% | ||
| Q2 25 | -19.5% | 58.6% | ||
| Q1 25 | -55.5% | 21.5% | ||
| Q4 24 | 4.0% | 24.9% | ||
| Q3 24 | -0.8% | 22.5% | ||
| Q2 24 | -22.5% | -2.8% |
每股收益（稀释后）ARDXRIGL
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.01 | $14.11 | ||
| Q3 25 | $0.00 | $1.46 | ||
| Q2 25 | $-0.08 | $3.28 | ||
| Q1 25 | $-0.17 | $0.63 | ||
| Q4 24 | $0.01 | $0.82 | ||
| Q3 24 | $0.00 | $0.70 | ||
| Q2 24 | $-0.07 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | $155.0M |
| 总债务越低越好 | $203.5M | $52.5M |
| 股东权益账面价值 | $148.6M | $391.5M |
| 总资产 | $504.5M | $513.6M |
| 负债/权益比越低杠杆越低 | 1.37× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ARDXRIGL
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | $155.0M | ||
| Q3 25 | $42.7M | $137.1M | ||
| Q2 25 | $90.0M | $108.4M | ||
| Q1 25 | $30.8M | $77.1M | ||
| Q4 24 | $64.9M | $77.3M | ||
| Q3 24 | $47.4M | $61.1M | ||
| Q2 24 | $41.9M | $49.1M |
总债务ARDXRIGL
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | $52.5M | ||
| Q3 25 | $202.1M | $60.0M | ||
| Q2 25 | $201.4M | $60.0M | ||
| Q1 25 | $151.3M | $60.0M | ||
| Q4 24 | $150.9M | $60.0M | ||
| Q3 24 | $100.7M | $60.0M | ||
| Q2 24 | $100.2M | $60.0M |
股东权益ARDXRIGL
| Q1 26 | $148.6M | — | ||
| Q4 25 | $166.9M | $391.5M | ||
| Q3 25 | $154.3M | $117.6M | ||
| Q2 25 | $139.5M | $81.9M | ||
| Q1 25 | $145.7M | $18.6M | ||
| Q4 24 | $173.3M | $3.3M | ||
| Q3 24 | $158.3M | $-14.6M | ||
| Q2 24 | $147.0M | $-29.9M |
总资产ARDXRIGL
| Q1 26 | $504.5M | — | ||
| Q4 25 | $501.6M | $513.6M | ||
| Q3 25 | $486.2M | $242.5M | ||
| Q2 25 | $466.8M | $206.7M | ||
| Q1 25 | $410.2M | $176.0M | ||
| Q4 24 | $435.8M | $164.0M | ||
| Q3 24 | $367.9M | $139.4M | ||
| Q2 24 | $343.5M | $128.4M |
负债/权益比ARDXRIGL
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | 0.13× | ||
| Q3 25 | 1.31× | 0.51× | ||
| Q2 25 | 1.44× | 0.73× | ||
| Q1 25 | 1.04× | 3.23× | ||
| Q4 24 | 0.87× | 18.25× | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | $22.0M | ||
| Q3 25 | $365.0K | $24.0M | ||
| Q2 25 | $-25.3M | $30.5M | ||
| Q1 25 | $-38.5M | $-893.0K | ||
| Q4 24 | $9.8M | $14.5M | ||
| Q3 24 | $501.0K | $21.7M | ||
| Q2 24 | $-19.4M | $302.0K |
自由现金流ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | — | ||
| Q3 25 | $209.0K | — | ||
| Q2 25 | $-26.0M | — | ||
| Q1 25 | $-38.8M | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $364.0K | — | ||
| Q2 24 | $-19.5M | — |
自由现金流率ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | -26.6% | — | ||
| Q1 25 | -52.3% | — | ||
| Q4 24 | 7.9% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | -26.7% | — |
资本支出强度ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.2% | — |
现金转化率ARDXRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | 2.11× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
RIGL
暂无分部数据
